BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report)'s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $320.94, but opened at $313.01. BeOne Medicines shares last traded at $315.12, with a volume of 20,493 shares traded.
Wall Street Analyst Weigh In
ONC has been the subject of several recent research reports. Guggenheim lifted their price target on BeOne Medicines from $350.00 to $365.00 and gave the company a "buy" rating in a research report on Thursday, August 7th. Morgan Stanley lifted their price target on BeOne Medicines from $313.00 to $330.00 and gave the company an "overweight" rating in a research report on Friday, June 27th. Barclays initiated coverage on BeOne Medicines in a research report on Thursday, September 18th. They issued an "overweight" rating and a $385.00 price target for the company. Wall Street Zen upgraded BeOne Medicines from a "buy" rating to a "strong-buy" rating in a research report on Friday, October 3rd. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of BeOne Medicines in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $340.30.
View Our Latest Research Report on ONC
BeOne Medicines Stock Performance
The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.72 and a current ratio of 1.95. The business has a 50 day moving average price of $323.15 and a two-hundred day moving average price of $277.58. The company has a market cap of $34.71 billion, a P/E ratio of -183.04 and a beta of 0.31.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.84 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.36. BeOne Medicines had a negative return on equity of 1.22% and a negative net margin of 3.89%.The company had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.24 billion. On average, sell-side analysts anticipate that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current year.
Insider Activity
In other news, COO Xiaobin Wu sold 49,858 shares of the business's stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $304.16, for a total value of $15,164,809.28. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Chan Henry Lee sold 11,013 shares of the company's stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $300.45, for a total value of $3,308,855.85. The disclosure for this sale can be found here. In the last three months, insiders have sold 164,184 shares of company stock worth $51,534,146. Company insiders own 6.62% of the company's stock.
Hedge Funds Weigh In On BeOne Medicines
Several institutional investors have recently bought and sold shares of the business. Anchor Investment Management LLC bought a new position in shares of BeOne Medicines in the 2nd quarter valued at about $26,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of BeOne Medicines in the 2nd quarter worth approximately $28,000. Daiwa Securities Group Inc. bought a new position in shares of BeOne Medicines during the 2nd quarter valued at approximately $35,000. Farther Finance Advisors LLC bought a new position in shares of BeOne Medicines during the 2nd quarter valued at approximately $39,000. Finally, Signaturefd LLC purchased a new stake in BeOne Medicines during the 2nd quarter valued at $49,000. Institutional investors own 48.55% of the company's stock.
About BeOne Medicines
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BeOne Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.
While BeOne Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
